Last reviewed · How we verify
ATGC Co., Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Xeomin® | Xeomin® | marketed | Botulinum toxin type A | SNARE complex (acetylcholine release machinery at neuromuscular junction) | Neurology / Aesthetics | |
| ATGC-110 | ATGC-110 | phase 3 | PD-1 inhibitor | PD-1 | Oncology |
Therapeutic area mix
- Neurology / Aesthetics · 1
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
- Addpharma Inc. · 1 shared drug class
- Asan Medical Center · 1 shared drug class
- Akeso · 1 shared drug class
- Amgen · 1 shared drug class
- Asahi Kasei Pharma Corporation · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- ASLAN Pharmaceuticals · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for ATGC Co., Ltd.:
- ATGC Co., Ltd. pipeline updates — RSS
- ATGC Co., Ltd. pipeline updates — Atom
- ATGC Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). ATGC Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/atgc-co-ltd. Accessed 2026-06-09.